Measuring cognition and function in the preclinical stage of Alzheimer's disease

The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Weintraub, Sandra, Carrillo, Maria C., Farias, Sarah Tomaszewski, Goldberg, Terry E., Hendrix, James A., Jaeger, Judith, Knopman, David S., Langbaum, Jessica B., Park, Denise C., Ropacki, Michael T., Sikkes, Sietske A.M., Welsh-Bohmer, Kathleen A., Bain, Lisa J., Brashear, Robert, Budur, Kumar, Graf, Ana, Martenyi, Ferenc, Storck, Marta Segardahl, Randolph, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021264/
https://www.ncbi.nlm.nih.gov/pubmed/29955653
http://dx.doi.org/10.1016/j.trci.2018.01.003
Descripción
Sumario:The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.

Ejemplares similares